M = T H O D S Figure 1. Study Design
a ; INT a ION This multicohort phase I/II trial, evaluated the safety and efficacy of Diseaseapecilic eolinte® ; n i i ‘ |
her Linda R Duska | LRD @uvahealth g pn a re conte tulmimetostat. The two cohorts presented here evaluated tulmimetostat as lexcres ans) Mt vort)
‘ monotherapy in patients with AR/D1Amut OCCC (Cohort M2) or EC (Cohort M3) | .
ee i ; The patients received one of the following three doses (Figure 1): | ve | Ss Se ee stage’: Sige
C rites 7 . im n=10 plus n=19
: : . : splays p a poorer fel r survival ! ne npared red to other e : : 350 ; ; i j x5 EC: endometrial carcinomat 200 mg: n=10 200 mg: n=10
_ mg continuous once daily (OD) dose in a dose expansion stage & : endometrial carcinoma per cohort except per cohort Close RP2D ig Dose ig.
P h ase | | d ose O ti Mmiz ati on sore OCs in reins mea waar ot pore ; Seog cetnuats nee ay Gn) oes p g as | w | enon contaniceen ee option =
h h yo HESS |P 2 g 3 9 SE SAFIVORR dose optimization 300 mg: n=10 expansion in 300 mg: n=10
. = i i 2 in M2/M3 cohort
. : : : a on To evaluate an optimal dose of tulmimetostat monotherapy, the phase II i in cohorts per cohort M2/M3 cohorts per cohort
d t th E 7 \-| 2/E 71H | h b t | Si ‘ave ARTO rt Fists oe th study design was updated to assess two additional doses of 300 mg and hi
u p rs | e WI | n | | O r 200 mg continuous OD dose * & fs Sank P
. ag ‘tage 2b initiates once either of the Stage 2a
oO * Dose optimization was conducted in two stages, Stage 2a and Stage 2b. a C predefined protocol criteria’ are met
tu | m ] m etostat D 7 R1 23/C P| -0209 In each cohort, Stage 2a comprises 20 patients, randomized 1:1 between 1. 22/10 ORR in a dose cohort
200 mg and 300 mg; Stage 2b enrolled up to 20 more patients in each cohort if 2. 1/10 ORR in a specific cohort
“ . a predefined protocol conditions were met in Stage 2a (Supported by totality of data)
] n pat ] e n ts with ARID 1A =“—MN u tated + Key eligibility criteria included adult patients with disease who had progressed $ SO ere meee mascked and
d lymphomas. na MW on applicable prior lines of treatment and met other tumor-specific inclusion (supported by totality of data)
+ = expansion and ele Ualas pempiotocolgand aellsted On) |nicalinalidoy *Patients in all cohorts have progressive disease with applicable prior lines of therapy; ‘Histologically or cytologically confirmed progressive tumor; Including GCB-DLBCL; *Stage 2b enrollment will be initiated if criterion in Stage 2a are
Ov rs | a rs | n Cc ea r ce Cc rs | rc ] n (@) Mm rs | (@) r . Primary endpoint was objective response rate (ORR) and secondary endpoint met as follows: Criteria 1 is met (22 responses in a dose cohort), or Criteria 2 is met (21 response in a specific dose cohort). Stage 2b enrollment may be initiated based on totality of safety, efficacy, and exposure-response data of that
cohort; or if Criteria 3 is met (no response in 300 mg cohort and 22/10 ORR in 200 mg cohort). Stage 2b may be opened for the 300 mg dose level based on totality of safety, efficacy, and exposure-response data
a) was safety DLBCL, diffuse large B-cell lymphoma; GCB, germinal center B-cell, ORR, objective response rate; PTCL, peripheral T-cell lymphoma; RP2D, recommended Phase || dose
endometrial carcinoma
R ES U LTS Figure 2. Best percentage change from baseline in target lesions across all dose levels (per RECIST 1.1) Table 3. Patients experiencing at least one TEAE possibly related (TRAE) to tulmimetostat
| occc Ec
As of March ‘ 2028, enrollment into the tulmimetostat an te ut ne pa rs 20110, 21/21, ; 7 a2 (OcCcC) M3 (EC) Events (n[%J) 200 mg 300 mg 350 mg 200 mg 300 mg 350mg
- 1 2) Am BR ; 4 an patients, in an cohorts respectively. Most patients in an cohorts receive 60 (N=20) (N=21) (N=14) (N=10) (N=21) (N=14)
Linda R Duska R D ska, Kalyan Banda, Ana Oaknin, Vincent Ribrag, 23 prior lines of therapy (Table 1) so | TRAE 18 (90.0) 21 (100) 14 (100) 8 (80.0) 21 (100) 11 (100)
Antonio Gonzalez Martin,° Nehal J Lakhani,° Jung-Yun Lee,’ * In EC, majority of patients (64-81%) enrolled had an ECOG performance status of 1. Notably, a numerically higher Grade 23 9 (45.0) 9 (42.9) 8 (57.1) 4 (10.0) 12 (57.1) 5 (45.5)
+3 . 9 . . : . 10 number of patients in 200 and 300 mg dose arms had ECOG status 1 compared with the 350 mg arm (Table 1) 40 Serious TRAE 3 (15.0) 2 (9.5) 3 (21.4) 0 5 (23.8) 3 (27.3)
Alok Tewani, Susana N Banerjee, Maria-Pilar Barretina-Ginesta, aoe TRAE leading to dose modification 9 (45.0) 14 (66.7) 11 (78.6) 6 (60.0) 16 (76.2) 10 (90.9)
ss 44 5 4 2 a 13 Table 1. Baseline and disease characteristics lies TRAE resulting in dose reduction 6 (30.0) 5 (23.8) 8 (57.1) 2 (20.0) 10 (47.6) 5 (45.5)
Valentin a Bo ni, Me hdi Brah mi, Lau nane E berst, Occc (N=55) EC (N=42) 204 TRAE leading to dose interruption 8 (40.0) 13 (61.9) 10 (71.4) 5 (50.0) 11 (62.4) 6 (54.5)
Jae Hoon Kim,'* Nicoletta Colombo, '® Domenica Lorusso,'®"” 200 mg 300 mg 360 mg 200 mg 300 mg 360 mg 10) TRAE leading to treatment discontinuation 2(10.0) 0 2143) 1 (10.0) 218.6) 181)
. 18 18 = : 18 (N=20) (N=21) (N=14) (N=10) (N=21) (N=11) ih 1 - li pase Teppnee asn 12s) for patients inne Sey ass + pete ia Ment A EC, endometrial carcinoma; OCCC, ovarian clear cell carcinoma;
Nicola Faulhaber, Lennart Kann, Anjali Thaku r, Sarees aL | | oe "treatment emergent adverse event; TRAE, TEAE possibly related to tulmimetostat
Charles Drescher’? Age (y) 50 (38-69) 55 (38-76) 54 (39-67) 62 (49-86) 64 (45-77) 67 (57-82)

median (range)

Time since initial

University of Virginia Health System, Charlottesville, VA, USA; @Seattle Cancer Care diagnosis (y) 2.2 (0.4-7.6) 2.2 (0.8-6.6) 3.5 (0.6-8.8) 4.1 (1.0-13.2) 3.2 (0.6-11.2) 3.2 (0.6-7.0)
Alliance, Seattle, WA, USA; Medical Oncology Service, Vall d’Hebron Institute of
Oncology, Vall d’Hebron Barcelona Hospital Campus, Barcelona, Spain; “Gustave

so
o

4

median (range)
Disease characteristic

Best Change (%) in Sum of Target Lesion Diameter from Baseline

; a || "i
10} || Figure 4. Frequently reported TEAEs (>15% either indication) possibly related (TRAEs) to tulmimetostat
20} m2(occc) M3 (EC)
304 J | 8 70 60 50 40 30 20 0 10 20 30 40 50 60 70 80
404 | Fatigue —_—_==_==_===__<
50} Thrombocytopenia —
ee

Lines of prior cancer —
Roussy, DITEP (Institut de Cancerologie Gustave-Roussy), Villejuif, France; SUniversity therapy, n(%) 7 |
re : ‘ : : ‘ 1 2 (10.0 2(9.5 4 (28.6) 1 (10.0 5 (23.8 2(18.2
Clinic of Navarra, Madrid, Spain; START Midwest, Grand Rapids, MI, USA; "Yonsei 2 ooo} Bee a To ea es 604 | a “Anaervia == a
Cancer Center and Severance Hospital, Yonsei University College of Medicine, Seoul, 3S eae ee oo Bae See) aoe -70+ SSS —
South Korea; ®Dana Farber Cancer Institute, Boston, MA, USA; Royal Marsden NHS EROS ae : , . . : . go Se Diarrhoea ————
Foundation Trust and Institute of Cancer Research, London, UK; ‘°University Hospital Status, n(%) °0 an! [
F : ane 1 : 7 . 7 : () 10 (50.0) 11 (52.4) 6 (42.9) 2 (20.0) 4 (19.0) 4 (36.4) 70° —SSS Vomitin _———
of Girona, Girona, Spain; : NEXT Oncology Madrid, University Hospital Quironsalud, Fi 10 (60.0) 40 (47.6) 8 (57,1) 8 (80.0) 47 (81.0) 7 (636) soo! ——eeEeEeEeEee 9 ——
Madrid, Spain; '*Centre Léon Bérard, Lyon, France; '*Strasbourg Europe Institut of EC, endometrial carcinoma: ECOG, eastern cooperative oncology group, OCC, ovarian clear cell carcinoma; y, years. Values have been reported as n(%) unless othemise specified . ci - 00 a pysgeusta ‘
sah 5 i : f OCCC Starting dose (mg): B 200mg ™ 300mg M 350mg EC Starting dose (mg): @ 200mg m 300mg m 350mg EE La
Cancerology, Strasbourg, EIaDee, Gangnam Severance Hospital, Yonsei University, Efficacy Data cutoft March 1, 202% "Complete response reported in target lesion
Seoul, Republic of Korea; European Institute of Oncology, IRCCS, Milan, Italy; EC, endometrial carcinoma, OCCC, ovarian clear cell carcinoma; RECIST, response evaluation criteria in solid tumours. ———_—_——_—_—_—_—_—_" Nausea =————
16 ; ; ; A ; : ; ; In OCCC, the highest confirmed ORR was reported for 200 mg dose (25%) and in the EC cohort, the highest confirmed . | | EE ST
Pepatinen of Biomedical Sciences, una nitas, University, Pieve Emanuele, Milan, ORR was reported for 350 mg dose (36.4%) (Table 2) Figure 3. Treatment duration and response assessment in the M2/M3 cohorts Alopecia ———
Italy; Humanitas San Pio X, Milan, Italy; '**MorphoSys GmbH, Planegg, Germany; . . - —_ . * > = x es | —— ae
19Swedish C Institute. Seattle. WA. USA * Inthe EC cohort, all responders experienced deep responses, with more than 50% reduction in target lesions. For the = = = — . | |
weaisn Cancer Institute, oeattle, , . OCCC cohort reductions ranged from 30% to 100% (Figure 2) = ° ae ==sssss=== Decreased appetite ==:
= = 3 x ee nay i—_—_—_—_*
* Of the 55 patients with OCCC (M2), 22 (40%) were on treatment for more than 5 months. Among these, 4/22 (18%) ——=—=—=—==—=—=— = 4 =a
remained on treatment at the time of data cutoff. For EC of 42 patients, 13 (31%) were on treatment for more than _— <= ° x 7 | Headache a2
5 months. Among these, 8/13 (62%) remained on treatment (Figure 3) ny = s SP .
. . . . a x = Neutropenia es
Table 2. Best confirmed and unconfirmed response per dose in OCCC and EC patients tJ = = — —
occc EC a ———— i x smn Weightdecreased = Samm
<i % _— SSS
200 mg 300 mg 350 mg 200 mg 300 mg 350 mg —_—"* ° xe
Antitumor activity in terms of objective responses and disease ria) N=20) Use al {N=is (N=10) teal) WEI —- “ x == Aspartate AT increased Ses
wpe . . Best confirmed response ie} ie} ie} ie} 1 (4.8) ie} asi
stabilization were observed in both OCCC and EC en Seema) ; ; ; ; as ten =e . — ‘Asthoria —
‘ , a k Pee dy. — —— =
Tumor regression was observed for both cohorts (OCCC and EC), with unconfirmed response —+, a L
tumor regression up to 100% Best confirmed response 5 (25.0) 3 (14.3) 1 (7.1) ie) 3 (14.3) 4 (36.4) ——————————————— J — Constipation
g P . . PR Becconnneds 7 (35.0) 3(14.3) 4 (28.6) 1 (10.0) 3 (14.3) 3 (27.3) ———== ‘i 7
Across three dose cohorts, 40% of patients with OCCC and 31% of ungoniimes|resnonse ————— x x — Epistaxis na
. . . , Best confirmed response 5 (25.0) 3 (14.3) 1 (7.1) (e) 4 (19.0) 4 (36.4) ee ee —_ a
patients with EC remained on treatment for more than 5 months ORR Fee espinal) =, a :
x =a
. (CR + PR) Unconrinméd|response 7 (35.0) 3 (14.3) 4 (28.6) 1 (10.0) 4 (19.0) 4 (36.4) o ~=_— — Abdominal pain
Safety data of tulmimetostat at 200 mg showed an acceptable safety In case of confirmed = ——— | a
er : . = ° x i i . _
profile in patients with ARID1Amut OCCC and EC compared to 300 and sp CRIPR oe) 10276) G{20-0) ESS) See) 32f3) * joe Alenine:Al.increasad = fmm
350 mg doses Biase ol unconiimes 7 (35.0) 10 (47.6) 4 (28.6) 7 (70.0) 6 (28.6) 3 (27.3) 2] Blood creatinine increased Sams
These updated findings in heavily pretreated patients with AR/D1Amut PD 5 (25.0) 8 (38.1) 6 (42.9) 1 (10.0) 9 (42.9) 3 (27.3) 0 1 2 8 4 5 6 7 8 9 1 1 42 13 14 45 16 17 18 19 2 21 22 23 24 25 26 27 28 29 cough
i i Discontinuation without response Time since first dose (months) = oud! 200 mg
Occc or EC support ongoing investigation of the dual EZH2/EZH1 eee 1 (6.0) 0 0 1 (10.0) 2(9.5) 1(9.1) S888 coast nl Sere AP on Bee ne ee — || 200 mg
inhibitor tulmimetostat Data cut-off: March 1, 2025. *Per RECIST v1.112. All values have been reported as n(%). CR, complete response, EC, endometrial carcinoma, OCCC, ovarian clear cell carcinoma, Assessment: =Complete response @ Partial response 4 Stable disease Progressive disease Death > Treatment ongoing a Dizziness —
ORR, objective response rate; PD, progressive disease; PR, partial response; RECIST, response evaluation criteria in solid tumours; SD, stable disease eaencen waren F088 eT | | 200 mg
Saf, EC, endometrial carcinoma, OCCC, ovarian clear cell carcinoma Lymphocyte count decreased —==—=—= All grade
afety = | 300 mg
Grade 23
Almost all patients experienced at least one treatment-emergent adverse events (TEAE) irrespective of causality in both Safety Neutrophil count decreased 00
OCCC and EC cohorts * Most common TEAEs (all grades) possibly related to tulmimetostat (TRAEs) included fatigue, thrombocytopenia, anemia il All aid
1 , 1 grade
To download a copy of this poster, visit the web at: — Serious TEAEs were frequent in OCCC 350 mg 57.1% (8/14) and EC 350 mg 72.7% (8/11) diarrhea, vomiting, dysgeusia, nausea, and alopecia (Figure 4) Platelet count decreased mam S50
Scan to https: //tinyurl.com/LindaR3102 : — Grade 23 for at least one TEAE was common in OCCC 350 mg 78.6% (11/14) and EC 300 mg 90.5% (19/21), while — About 15% in OCCC and 19% in EC had a serious TRAE with 47% in OCCC and 43% in EC having at least one | ee | Co Grade 23
ebtin the grade 23 serious TEAEs were common in OCCC 350 mg 57.1% (8/14) and EC 350 mg 63.6% (7/11) dose arms TRAE of grade 23 (Table 3) -_= Pruritus il 350 mg
Bostsy Cue o this poster oblained ee chia sibe — Highest incidence of TEAEs requiring dose reductions occurred in OCCC 350 mg 64.3% (9/14) and in EC 300 mg — Most grade 23 TRAEs were hematologic and more common with 300 and 350 mg doses. High incidence of grade P = Rash — All grade
COderare;(Of personal USeOn|y"ane:maysnot Oe 52.4% (11/21) 23 anemia were observed in 350 mg OCCC (50%) and 300 mg EC (29%), thrombocytopenia in 350 mg OCCC (29%) —e—
reproduced without written permission of the authors. — Highest treatment discontinuations due to TEAEs were reported in the OCCC 350 mg 14.3% (2/14) and in and 300 mg EC (10%). Diarrhea, another common grade 23 TRAE, was reported in 300 mg OCCC (24%) and 350 mg bate cuteft march 1 2026. AT amanctraneterase: EC: endemetia GERD. castocsooneacal etn d Lb lectate dehy ocee lear cel
EC 200 mg 20.0% (2/10) cohorts. No TEAEs led treatment discontinuations in the OCCC 300 mg cohort EC (18%) (Table 3 and Figure 4) TEAR, treatment emergent adverse event: TRAE TEAE possibly relatedtotummetostat na
References Acknowledgments Disclosures
1. Bitler BG, et al. Nat Med 2015;21(3):231-38. 5. Roh JWet al. Cancer Biol Ther. 2020:21(2):147-156. 9. Wu R, et al. Cancer Res 2021;81 (Suppl 13). The ales tne ale orale inti aed ace enemies eae ue . a Linde Dus ete mnetition researct nds fom Abeer Aire Bigiget Advats, lemme centals stot Myers Sued:
. . my e s & “ - 10. ClinicalTrials.gov. NCT04104776 www.clinicaltrials.gov/study/NCT041 04776 [Accessed 15 May, 2025]. investigators. é authors than snwinl Kumar, jarmD, an ijl Joseph, ic, both of Novartis erulean arma, Genentec! ocne, jaxOomii ine, Leap jerapeutics, Ludwig Institute for Cancer Researcn, Merck,
This study was sponsored by Novartis Pharma AG, Basel, Switzerland. 2. Eich ML, et al. Cancer Res 2020;80(24):5449-58. ch Es Peo. a| Cancers: oe Neb 1) 250. 41. Oaknin A. et al. ESMO 2024, Poster-748P. Healthcare Pvt Ltd (Hyderabad, India), for providing medical editorial assistance in the Millennium, Morab, Morphotek, Novartis, Pfizer, Syndax, and Tesaro. Institution payments for her role in the Monitoring and
Post ted at: The A . Society of Clinical O (ASCO) A | Meeti 3. Maeda D, et al. nt J Mol Sci 2010;11(12):5120-28. 7. Lid, etal. J Clin Invest 2020;130(5):2712-26. 10 eet in : ‘ eas) a ao Bhar preparation of this poster, in accordance with Good Publication Practice (GPP3) guidelines Advisory Boards of Innovio, Aegenus, and Merck, and personal fees from Daiichi Sankyo.
oster presented al: [ne American society of Clinical Oncology hnua! Meeting; 4. Liu Z, et al. J Ovarian Res 2024;17(1):39. 8. Lakhani Nu, et al. J Clin Oncol 2021;39 (Suppl 15):3104. peso SSP Picola

May 30 - June 3, 2025; Chicago, IL, US.

